Cuper Martinez, MD

Dr. Cuper Martinez is happily married with a 2- and 4-year-old who makes his life interesting. He loves watching them play soccer and swimming.

Professional Experience:

• Present Principal Investigator Kalo Clinical Research, Salt Lake City, UT
• Hospitalist Jordan Valley Medical Center Main and West Campus, West Jordan, UT
• Provider Hospice and Palliative Medicine Salt Lake City, UT
• Department of Internal Medicine Chair Jordan Valley Hospital, West Jordan, UT
• Outpatient Internal Medicine Western Hills, West Valley City, UT
• Outpatient Internal Medicine Sacred Circle Healthcare West, Valley City, UT

Research Experience:

• Principal Investigator, SELECT – Semaglutide effects on cardiovascular outcomes in people overweight or with obesity.
• Principal Investigator, A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose
  values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus.
• Sub Investigator, Protocol I8F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular
  Events in Patients with Type 2 Diabetes (SURPASS-CVOT).
• Sub Investigator, A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable
  Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose
  Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and
  Adolescent Participants with Inadequately Controlled Asthma (KALOS).
• Sub-Investigator, Treatment Use Study of Patients Safety Following Transfusion of Intercept Platelet Components
  Principal Investigator, A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of
  IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to
  Hypertensive Patients with Uncontrolled Blood Pressure.
• Sub Investigator, Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy,
  Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis
  Bronchiectasis – The ASPEN Stud.